Geomatrix is a registered trademark of Jagotec AG. Shionogi Inc.’s use of the Geomatrix technology is under license from SkyePharma.

Available in 8.5 mg, 17 mg, 25.5 mg, and 34 mg tablets, SULAR is a once-a-day dosing proven to provide 24-hour control for the treatment of hypertension.1

NDC Numbers
8.5 mg 59630-500-10
17 mg 59630-501-10
25.5 mg 59630-502-10
34 mg 59630-503-10

Product Description

SULAR extended release tablets in 8.5 mg and 17 mg are round, film-coated tablets. The 25.5 mg and 34 mg tablets are elliptic, film-coated tablets. The different strengths can be identified as follows:


Strength Color Markings
8.5 mg Oyster SCI 500
17 mg Yellow Cream SCI 501
25.5 mg Mustard SCI 502
34 mg Burnt Orange SCI 503

All strengths are formulated in an extended-release Geomatrix® Delivery System that allows for 15% less nisoldipine per dose. 2


WAC (as of 3-13-08)
8.5 mg $181.69 per bottle of 100
17 mg $227.72 per bottle of 100
25.5 mg $248.34 per bottle of 100
34 mg $248.34 per bottle of 100

Customer inquiries, product and ordering information may be directed to Customer Relations by calling 1-800-849-9707.

Indication:
SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

 

Important Safety Information:
The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.

 

Please click here for full prescribing information.


Your Healthcare Provider can give you more information about Sular or call (800) 849-9707 ext 1454. Ask your Healthcare Provider if Sular may be right for you.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Images are for illustrative purposes only.


References: 1. Punzi HA, Noveck R, Weiss RJ, et al. Are there differences in the effects of long-acting calcium antagonists on amblatory blood pressure? Extended-Release nisoldipine versus amlodipine as a model. Blood Press Monit. 1998;3:267-272. 2. Data on file. Shionogi Inc.

back to top